US · PRPO
Precipio, Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- New Haven, CT 06511
- Website
- precipiodx.com
Price · as of 2024-12-31
$30.94
Market cap 42.19M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $1,032.79 | +3,238.04% |
| Intrinsic Value(DCF) | $448.42 | +1,349.32% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $0.00 | $3,287.27 | |||
| 2011 | $0.00 | $0.00 | |||
| 2012 | $0.00 | $0.00 | |||
| 2013 | |||||
| 2014 | |||||
| 2015 | $0.00 | $1,964,032.03 | |||
| 2016 | $0.00 | $0.00 | |||
| 2017 | $151.80 | $6,928.04 | $0.00 | $0.00 | $0.00 |
| 2018 | $43.50 | $58.74 | $0.00 | $0.00 | $0.00 |
| 2019 | $27.40 | $58.27 | $36.42 | $0.00 | $0.00 |
| 2020 | $50.60 | $312.24 | $12,181.71 | $0.00 | $0.00 |
| 2021 | $26.80 | $139.57 | $13,196.23 | $0.00 | $0.00 |
| 2022 | $13.24 | $14.47 | $5,121.25 | $0.00 | $0.00 |
| 2023 | $6.21 | $576.85 | $8,527.60 | $0.00 | $0.00 |
| 2024 | $6.93 | $1,032.79 | $1,689.33 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Precipio, Inc.'s (PRPO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $1,032.79
- Current price
- $30.94
- AI upside
- +3,238.04%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$448.42
+1,349.32% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PRPO | Precipio, Inc. | $30.94 | 42.19M | +3,238% | +1,349% | — | — | -2.37 | 0.84 | 0.64 | -3.70 | — | 45.11 | 47.35% | -26.41% | -26.87% | -32.35% | -32.43% | -24.45% | 0.10 | -56.97 | 0.81 | 0.51 | 0.05 | -3503.00% | 505.00% | -10586.00% | 2.13% | 0.10 | 1.66% | 0.00% | 0.00% | 0.00% | -2.37 | 46.36 | 0.63 | -7.13 |
| INTS | Intensity Therapeutics, I… | $7.66 | 14.45M | — | — | — | — | -1.89 | 10.53 | — | -1.74 | — | 10.53 | 0.00% | — | — | -202.34% | 3350.51% | -147.37% | 0.05 | — | 1.92 | 1.48 | 0.15 | -1522.00% | — | 11124.00% | -49.52% | -8.67 | 3074.75% | 0.00% | 0.00% | 0.00% | -1.71 | -1.86 | — | -20.70 |
| ITRM | Iterum Therapeutics plc | $0.26 | 13.97M | — | — | — | — | -1.10 | -6.66 | — | -2.24 | — | -1.14 | 0.00% | — | — | 472.61% | -628.33% | -69.93% | -11.16 | — | 1.41 | 1.37 | -0.99 | -5743.00% | — | -3195.00% | -98.48% | -1.52 | -899.75% | 0.00% | 0.00% | 0.00% | -2.60 | -1.82 | — | -16.11 |
| MODD | Modular Medical, Inc. | $0.25 | 15.64M | — | — | — | — | -1.66 | 1.83 | — | -1.09 | — | 1.83 | 0.00% | — | — | -131.58% | -459.49% | -115.69% | 0.05 | — | 10.69 | 10.41 | 0.71 | -3462.00% | — | 1636.00% | -58.31% | -12.43 | -439.34% | 0.00% | 0.00% | 13.57% | -1.00 | -1.04 | — | 2.40 |
| PLUR | Pluri Inc. | $3.60 | 29.39M | +873% | -44% | — | — | -1.37 | -4.65 | 23.81 | -2.05 | — | -2.49 | 48.95% | -1659.88% | -1690.34% | 689.30% | -701.84% | -59.46% | -4.98 | -25.40 | 0.68 | 0.66 | -1.28 | -1078.00% | 30982.00% | 810.00% | -62.33% | -0.56 | -627.70% | 0.00% | 0.00% | 0.00% | -2.04 | -2.28 | 33.87 | -17.73 |
| POCI | Precision Optics Corporat… | $4.28 | 33.04M | +286% | +2,105% | — | — | -5.25 | 2.48 | 1.59 | -5.73 | -7.15 | 9.48 | 17.83% | -29.08% | -30.28% | -51.78% | -43.34% | -31.50% | 0.17 | -24.45 | 1.64 | 0.99 | -0.05 | 7347.00% | -7.00% | 2680.00% | -12.44% | -0.58 | -29.47% | 0.00% | 0.00% | 9.11% | -5.52 | -8.11 | 1.60 | -1.34 |
| RBOT | Vicarious Surgical Inc. | $2.04 | 13.19M | — | — | — | — | -0.87 | 1.17 | — | -0.32 | — | 1.17 | 0.00% | — | — | -87.40% | -511.76% | -67.41% | 0.30 | — | 6.74 | 6.40 | -0.07 | -2658.00% | — | -2163.00% | -91.59% | -6.52 | -385.51% | 0.00% | 0.00% | 0.00% | -0.29 | -0.39 | — | -4.95 |
| STRR | Star Equity Holdings, Inc… | $9.98 | 34.29M | +11,500% | +1,775,496% | — | +1,761% | -3.07 | 0.79 | 0.60 | -3.35 | -1.19 | 1.00 | 20.72% | -15.77% | -19.56% | -23.46% | -32.46% | -18.39% | 0.03 | — | 3.58 | 3.31 | 3.31 | 25766.00% | -6693.00% | -50185.00% | -25.05% | -0.46 | -31.00% | 6.36% | -19.50% | 7.23% | -1.92 | -2.01 | 0.30 | -8.72 |
About Precipio, Inc.
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
- CEO
- Ilan Danieli
- Employees
- 54
- Beta
- 1.22
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($448.42 ÷ $30.94) − 1 = +1,349.32% (DCF, example).